Current Studies

Clinical trials are vital in developing and evaluating new treatments for children with rheumatologic diseases.

Studies currently being conducted by the PRCSG include:

Title Sponsor
A Long-term, Multicenter, Longitudinal Post-marketing, Observational Registry to Assess Long Term Safety and Effectiveness of Humira (adalimumab) in Children with Moderate to Severe Active Polyarticular or Polyarticular Course Juvenile Idiopathic Arthritis (JIA) - STRIVE AbbVie
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis Bristol-Myers Squibb
A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy Janssen Research & Development, LLC
A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus GlaxoSmithKline
A study to evaluate decreased dose frequency in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA) who experience laboratory abnormalities during treatment with tocilizumab Hoffman-La Roche
Long-Term extension study to evaluate the safety and efficacy of subcutaneous tocilizumab in patient with polyarticular-course and systemic juvenile idiopathic arthritis Hoffman-La Roche
Secukinumab Safety and Efficacy in JPsA and ERA Novartis Pharmaceuticals
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) Novartis Pharmaceuticals
A Long-term, Open-label Follow-up Study Of Tofacitinib For Treatment Of Juvenile Idiopathic Arthritis (Jia) Pfizer
Efficacy, Safety And Tolerability Of Tofacitinib For Treatment Of Polyarticular Course Juvenile Idiopathic Arthritis (Jia) In Children And Adolescent Subjects Pfizer
A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA Pfizer
Pediatric Arthritis Study of Certolizumab Pegol (PASCAL) UBC, Inc